

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jane C. Hirsch, Kamal K. Midha, Mark Hirsch, and Whe-Yong Lo

Serial No.: 09/858,016

Art Unit:

1616

Filed:

May 15, 2001

Examiner:

S. Gollamundi

For:

PHARMACEUTICAL COMPOSITIONS FOR BOTH INTRAORAL AND ORAL

ADMINISTRATION

Assistant Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit a Supplemental Information Disclosure Statement, including two (2) pages of Form PTO-1449, copies of fourteen (14) documents cited therein, and a copy of the European Search Report, mailed July 10, 2002, in the corresponding European application EP 02 00 7778.

It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 50-1868.

Certification Under 37 C.F.R. §1.97 (e)(1)

Each item of information contained in this Supplemental Information Disclosure

Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information

Disclosure Statement.

U.S. Patents

Number	Publication Date	<u>Patentee</u>	Class/Subclass
2001/0002999	06-07-2001	Neuser, et al.	424/464
4,139,589	02-13-1979	Beringer, et al.	264/250
5,407,686	04-18-1995	Patel, et al.	424/468
5,609,884	03-11-1997	Desai	424/468
5,702,723	12-30-1997	Griffin	424/463
6,372,255	04-16-2002	Saslawski, et al.	424/473

Foreign Documents

Number	Publication Date	Patentee	Country
2.772-615	-06-25-1999	Lipha	-FR
0 584 594	03-02-1994	Gergely Gerhard	EP
1 044 680	10-18-2000	Beecham Pharmaceuticals	EP
1 112 737	07-04-2001	Hennig Arzneimittel GMBH	EP
800 973	09-03-1958	Sterling Drug Inc.	GB
WO 98/46235	06-07-2001	Bayer Aktiengesellschaft	PCT
WO 00/35296	06-22-2000	W.M. Wrigley Jr. Company	PCT
WO 01/37814	05-31-2001	Robert Gordon University	PCT

U.S.S.N.:

09/858,016

Filed:

May 15, 2001

SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

Patrea L. Pabst

Reg. No. 31,284

Dated: November 15, 2002

HOLLAND & KNIGHT LLP One Atlantic Center 1201 West Peachtree Street, N.E. Suite 2000 Atlanta, Georgia 30309-3400 404-817-8473 FAX 404-817-8588

www.hklaw.com

U.S.S.N.:

09/858,016

Filed:

May 15, 2001

SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT

Certificate of Mailing under 37 CFR §1.8(a)

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date:

November 15, 2002

Erica C. Boughned

ATL1 #552281 v1



SUPPLEMENTAL INFORMATION DISC STATEMENT CHECKLIST	CLOSURE TENTED TO LOSURE TENTED TO T
Client and Matter Name:	CP 10 8
Client #/ Matter #:	085337/00009
Attorney and Due Date Pabst	
Check Requested <u>N/A</u>	
I have checked the following sources for references to be cited in Supplemental IDS: X Application and PTO Correspondence File	the IDS and/ or
Application	· .
X IDS/ Supp. IDS	
X Office Action/ PTO-892	
Other	
X PCT File	· ,
PCT Written Opinion	
International Search Report	•
X Other <u>European Search Report</u>	
Suggestions/Requests for other sources:	
Gue Eric	a C. Boughner

ATL1 #552307 v1